Brief: Cognition Therapeutics Completes Enrollment In Phase II Shimmer Study Of CT1812 In Mild-To-Moderate Dementia
29/04/2024 12:40
April 29 (Reuters) - Cognition Therapeutics Inc
CGTX.O :
* COGNITION THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2
SHIMMER
STUDY OF CT1812 IN MILD-TO-MODERATE DEMENTIA WITH LEWY BODIES
* COGNITION THERAPEUTICS INC: TOP-LINE RESULTS ARE EXPECTED
IN
SECOND HALF OF 2024 AFTER LAST PARTICIPANTS HAVE COMPLETED SIX
MONTHS OF TREATMENT
Source text for Eikon: ID:nGNX8p1nPn
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB